CSIMarket Company Name, Ticker, Suppliers, else..
 
Nuvectis Pharma inc   (NASDAQ: NVCT)
Other Ticker:  
 
 
Price: $9.8100 $-0.39 -3.824%
Day's High: $10.67 Week Perf: 3.92 %
Day's Low: $ 9.52 30 Day Perf: 29.25 %
Volume (M): 140 52 Wk High: $ 11.80
Volume (M$): $ 1,377 52 Wk Avg: $6.69
Open: $10.20 52 Wk Low: $4.44



 Market Capitalization (Millions $) 168
 Shares Outstanding (Millions) 17
 Employees 17
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Nuvectis Pharma Inc
Nuvectis Pharma Inc is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for various medical conditions. The company is dedicated to improving patient outcomes and addressing unmet medical needs. With a team of experienced scientists and researchers, Nuvectis Pharma works to discover and develop novel drugs, leveraging cutting-edge technologies and scientific advancements. The company aims to bring safe and effective treatments to market, ultimately improving the quality of life for patients worldwide.


   Company Address: 1 Bridge Plaza Fort Lee 7024 NJ
   Company Phone Number: 614-3150   Stock Exchange / Ticker: NASDAQ NVCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AKBA   -20%    
BMY        1.92% 
HCM        0.94% 
RYTM        2.73% 
SUPN        1.3% 
YMAB        13.66% 
• View Complete Report
   



Business Update

Nuvectis Pharma Shows Promise in NSCLC Treatment Despite Revenue Challenges

Published Sat, Mar 8 2025 9:24 AM UTC

In a recent announcement, Nuvectis Pharma (NASDAQ: NVCT) reported encouraging findings from a study conducted at the Cleveland Clinic s Lerner Research Institute. The study, published in the peer-reviewed journal Molecular Cancer Research, evaluated the efficacy of NXP900, a novel therapeutic candidate, in combination with osimertinib (Tagrisso) for the treatment of non-smal...
Clinical Study

A Pioneering Advance in Oncological Pharmacology The Granting of Orphan Drug Designation for NXP800

Published Thu, Aug 29 2024 12:01 PM UTC

In the evolving landscape of oncological therapeutics, the recent announcement from Nuvectis Pharma, Inc. regarding the Orphan Drug Designation granted by the venerable United States Food and Drug Administration (FDA) merits commendation and thorough examination. This notable designation pertains to NXP800, an emergent pharmacological agent designated for the treatment of ma...
Nuvectis Pharma Inc

Nuvectis Pharma Inc Faces Corporate Performance Reduction in First Quarter of 2024

Nuvectis Pharma Inc, a major pharmaceutical preparations company, surprised shareholders with unexpected modifications to its top-line during the earnings season from January to March 31, 2024. The company reported an operating deficit of $-4.396 million during this period, which was a cause for concern among investors.
To put this into perspective, it is worth noting that in the first quarter of 2022, Nuvectis Pharma Inc reported an operating deficit of $-2.945 million. Therefore, the deficit has intensified significantly from $-2.943 million, compared to the same period a year before. This raises questions about the company's financial stability and performance.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com